Gastrointestinal stromal tumours
Gastrointestinal stromal tumours (GIST) have an incidence of~ 1.2 per 105 individuals per
year in most countries. Around 80% of GIST have varying molecular changes, predominantly …
year in most countries. Around 80% of GIST have varying molecular changes, predominantly …
Therapeutic advances of targeting receptor tyrosine kinases in cancer
Receptor tyrosine kinases (RTKs), a category of transmembrane receptors, have gained
significant clinical attention in oncology due to their central role in cancer pathogenesis …
significant clinical attention in oncology due to their central role in cancer pathogenesis …
Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up
Highlights•This clinical practice guideline provides key recommendations on the
management of gastrointestinal stromal tumours.•Recommendations have been agreed …
management of gastrointestinal stromal tumours.•Recommendations have been agreed …
Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
PG Casali, N Abecassis, S Bauer, R Biagini… - Annals of …, 2018 - annalsofoncology.org
Gastrointestinal stromal tumours (GISTs) are rare tumours, with an estimated unadjusted
incidence of around 1/100 000/year [1]. This only covers clinically relevant GISTs, since, if …
incidence of around 1/100 000/year [1]. This only covers clinically relevant GISTs, since, if …
International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers
L Amar, K Pacak, O Steichen, SA Akker… - Nature Reviews …, 2021 - nature.com
Approximately 20% of patients diagnosed with a phaeochromocytoma or paraganglioma
carry a germline mutation in one of the succinate dehydrogenase (SDHx) genes (SDHA …
carry a germline mutation in one of the succinate dehydrogenase (SDHx) genes (SDHA …
Therapeutic implications of germline testing in patients with advanced cancers
PURPOSE Tumor mutational profiling is increasingly performed in patients with advanced
cancer. We determined the extent to which germline mutation profiling guides therapy …
cancer. We determined the extent to which germline mutation profiling guides therapy …
The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines
Although gastrointestinal stromal tumors (GISTs) are a rare type of cancer, they are the
commonest sarcoma in the gastrointestinal tract. Molecularly targeted therapy, such as …
commonest sarcoma in the gastrointestinal tract. Molecularly targeted therapy, such as …
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised …
Background Until now, only imatinib and sunitinib have proven clinical benefit in patients
with gastrointestinal stromal tumours (GIST), but almost all metastatic GIST eventually …
with gastrointestinal stromal tumours (GIST), but almost all metastatic GIST eventually …
Molecular subtypes of KIT/PDGFRA wild-type gastrointestinal stromal tumors: a report from the National Institutes of Health Gastrointestinal Stromal Tumor Clinic
SA Boikos, AS Pappo, JK Killian, MP LaQuaglia… - JAMA …, 2016 - jamanetwork.com
Importance Wild-type (WT) gastrointestinal stromal tumors (GISTs), which
lackKITandPDGFRAgene mutations, are the primary form of GIST in children and …
lackKITandPDGFRAgene mutations, are the primary form of GIST in children and …
Gastrointestinal stromal tumour
H Joensuu, P Hohenberger, CL Corless - The Lancet, 2013 - thelancet.com
Gastrointestinal stromal tumours (GISTs) are mesenchymal neoplasms that arise in the
gastrointestinal tract, usually in the stomach or the small intestine and rarely elsewhere in …
gastrointestinal tract, usually in the stomach or the small intestine and rarely elsewhere in …